1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- DSP to End Sales of Melbin
September 14, 2011
- Medipal HD, JCR Announce Codevelopment Agreement for 3 Products
September 14, 2011
- FDA Advisory Committee Recommends Approval of Rivaroxaban for SPAF
September 13, 2011
- AZ, Daiichi Sankyo to Launch Nexium on Sept. 15
September 13, 2011
- Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan
September 13, 2011
- NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
- TransGenic Submits Patent Application for Novel Lung Cancer Marker Antibody
September 12, 2011
- Santen to Enhance Sales Functions by Creating New Group
September 12, 2011
- Toho Pharmaceutical to Acquire Shouei in January 2012
September 12, 2011
- Astellas to Transfer Distribution Rights for Targocid, Maalox to sanofi-aventis
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
- Pfizer’s Novel NSCLC Treatment Crizotinib Receives Approval in US
September 12, 2011
- Bayer’s Alpharadin to Be Granted Fast Track Review Status from FDA
September 12, 2011
- Ethical Drugs Sales Rise 5.3% in 2nd Quarter: IMS Japan
September 12, 2011
- Market for Anti-RA Drugs to Exceed ¥300 Bil. in 2019: Fuji-Keizai
September 12, 2011
- Mizuho Forecasts Higher Sales, Lower Profits for 9 Major Domestic Drug Makers in FY2011
September 12, 2011
- Nomura Securities Raises Target Share Prices for 3 Drug Wholesalers
September 12, 2011
- Kissei Obtains Japan Rights for Anthracycline Extravasation Agent
September 12, 2011
- Astellas Licenses Fully-Human Antibody against Infectious Diseases from Evec
September 12, 2011
- Drug-only Warehouses at Haneda Airportto Start Full-scale Operations this Fall
September 12, 2011
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…